Third Wave/Stratagene resolve patent litigation

5 February 2007

US firms Third Wave Technologies and Stratagene Corp have reached an out-of-court settlement regarding the matter litigated in US District Court in Wisconsin in September 2005 and appealed to the Federal Circuit in Washington DC.

Stratagene has agreed to pay Third Wave $10.75 million in cash as full satisfaction for the judgment. The companies said they would stay any further litigation for nine months. The companies have also agreed to a process to resolve that case or any other disputes through an accord that enables either firm to elect to arbitrate a patent dispute or to resolve it through a royalty-bearing license.

Joseph Sorge, chief executive of Stratagene, said: "with this settlement, we will be able to redeem our $21.0 million appeal bond and strengthen our balance sheet by $10.25 million. In addition, the resolution of this issue will also enable our management team to focus more resources on executing our long-term growth strategy in molecular diagnostics, including the pursuit of additional partnerships and product development opportunities."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight